Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : VALANX Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
VALANX Biotech And Fina Biosolutions Launch ClickCRM for Vaccine R&D
Details : The licensing agreement will commercialize ready-to-conjugate vaccine carrier protein CRM197 enabling rapid development of conjugate vaccines such as the pneumococcal and meningococcal vaccines.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 29, 2024
Lead Product(s) : Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : VALANX Biotech
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?